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CHAPTER 1 INTRODUCTION 
1.1 INTRODUCTION TO DIABETES AND INSULIN SIGNALING PATH-
WAY 
1.1.1 INTRODUCTION TO DIABETES 
 
Diabetes is a metabolic disorder characterized by high blood glucose.  Accord-
ing to the National diabetes statistics report, by 2012, 29.1 million of the U.S population 
had diabetes. Out of which 21 million are diagnosed and 8.1 million undiagnosed. 1.7 
million New cases of diabetes have been diagnosed in 2012. 86 million aged 20 or older 
had pre-diabetes in 2012 compared to 79 million in 2010 which went high by 7 million. 
In 2010, it was the 7th leading cause of death. There are many complications associated 
with diabetes besides high blood glucose levels. Eventually, they can have impaired 
functioning of heart, kidneys, nerves, eyes and blood vessels. These people have higher 
risk for stroke and heart disease1. Neuropathy (nerve damage) is other common effect. 
This increases the incidence of foot ulcers, infections and also can lead to limb ampu-
tations. Diabetic retinopathy associated blindness accounts for 1% of the global blind-
ness2. Diabetes can also lead to kidney failure3.  
There are two major types of diabetes: type I and type II.  Type II Diabetes 
accounts for 90-95% of all diabetic cases. Type I Diabetes is seen in children and young 
adults due to the lack of insulin production caused by the loss of pancreatic beta cells. 
This is also called insulin dependent diabetes mellitus. Type II Diabetes occurs in rela-
tively older people, which is the consequence of a combination of insulin resistance and 
relative insulin deficiency4.    
  Insulin is a hormone produced by the islet cells in response to the rise in blood 
glucose levels4. More than 70% of insulin-stimulated glucose uptake takes place in 
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skeletal muscle. Insulin resistance in skeletal muscle is one of the major defects in Type 
II diabetes4. 
1.1.2 INSULIN SIGNALING PATHWAYS 
 
Insulin increases glucose uptake, synthesis of proteins, lipids and glycogen 
through activation of various pathways in skeletal muscle cells.  Insulin binds to the 
insulin receptor, a tyrosine kinase receptor, causes the activation of the receptor that 
triggers cascades of events. The various substrates for the insulin receptor include in-
sulin receptor substrate 1 (IRS1), P60, Gab-1, cbl and Isoforms of shc. The phosphor-
ylated tyrosines on these substrates allow them to bind to various downstream mole-
cules, which include P85 subunit of the phosphatidylinositide 3 kinase (PI3K), Grb2, 
crk II, etc. PI3K binds to IRS1, which activates Akt to enhance GLUT4 translocation 
and thereby glucose uptake, glycogen synthesis, and protein synthesis.  Insulin also 
activates mitogen-activated protein kinases (MAPK) to increase gene expression and 
differentiation5.   
1.2 KINASES AND PHOSPHATASES 
 Phosphorylation is one of the most important post translational modifications 
which regulates most signaling molecules in the cell. This process is carried out by 
kinases contrary to the phosphatases which carry out dephosphorylation. Of all the pro-
teins in the eukaryotic cell, one third portions undergo reversible phosphorylation6. 
Phosphatases remove phosphate group by nucleophilic attack in the presence of water. 
Phosphorylation and dephosphorylation are mostly carried out on amino acids contain-
ing OH group such as serine, threonine and tyrosine. Among these, serine undergoes 
almost 86.4% of the total phosphorylation followed by threonine (11.8%) and tyrosine 
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(1.8%)7. Kinases are classified as protein tyrosine kinases and serine/threonine kinases. 
Characterization of phosphatases is based on their substrates: 
i. Protein Tyrosine Phosphatases (PTP): remove the phosphate group from 
phosphorylated tyrosine residues. 
ii. Protein Serine/Threonine Phosphatases: remove the phosphate group from 
phosphorylated serine/threonine residues. This group is Further classified 
into Phospho Protein Phosphatase (PPP) which includes PP1, PP2A, PP2B, 
PP4, PP5, PP6, PP7 and Metal ion (Mg+2 and Mn+2) dependent phosphatase 
(PPM) which includes PP2C. 
iii. Dual specificity protein serine/threonine/tyrosine phosphatase. 
iv.  Histidine phosphatase 
v. Lipid phosphatase. 
As their names suggest, their substrates involve phosphorylated tyrosine, ser-
ine/threonine, serine/threonine/tyrosine, or histidine residues and lipids, respectively. 
The number of genes coding kinases approximately 3 fold higher than that of 
phosphatases8. Balancing the large number of kinases is achieved by the presence of 
various isoforms of each subunit composing the phosphatases. Phosphatases are com-
plexes, generally composed of a catalytic subunit and one or more regulatory subunits. 
The catalytic subunit itself is relatively non-specific and can dephosphorylate numerous 
substrates.  Therefore, the interaction between the catalytic subunit and regulator sub-
units is required to regulate the specificity and activity of the phosphatases8. 
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1.3 PROTEIN PHOSPHATASE 2A (PP2A), REGULATION AND EFFECT OF 
INSULIN 
PP2A is a one of the major serine-threonine protein phosphatase that belongs to 
the phosphoprotein phosphatase family. This phosphatase constitutes for about 1% of 
the total protein in the cell9. It is a hetero trimeric complex with a dimeric core enzyme 
(see Figure 2), composed of a 65kda A subunit (PP2Aa), a 55kda B regulatory subunit 
(PP2Ab), and a 36kda catalytic subunit C (PP2Ac). Subunits A and C form the dimeric 
core10.  
1.3.1 SUBUNITS OF PP2A 
 
PP2Aa (A regulatory subunit) is ubiquitous and has two isoforms, alpha and 
beta, which are encoded by two different genes PPP2R1A and PPP2R1B. There is 86% 
similarity between these two isoforms. The dimer core, in most cases (90%), is com-
posed of A alpha isoform9. Both the isoforms are located in the cytoplasm. It is com-
posed of 15 non-identical repeats (HEAT sequence) containing 39 amino acids each. 
The repeats contain two alpha helices which are connected to each other by intra and 
inter repeat loops forming a horse-shoe shape. B subunit binds to loops 1-10 whereas 
C subunit binds to loops 11-1511. Because of its flexibility, B subunits and other sub-
strates can be incorporated easily9. PP2Aa guides PP2Ac in the interaction with PP2Ab 
and other substrates and regulates the specificity of PP2Ac12. 
PP2Ab (B regulatory subunit) regulates localization, activity and substrates for 
the complex. This regulatory subunit is encoded by 15 different genes which are tran-
scribed to a minimum of 26 transcripts and splice variants. They are expressed variably 
depending on the tissue type. They are classified as B (B55/PR55), B’ (B56/PR61), B‘’ 
(PR48/PR72/PR130), and B‘’’ (PR93/PR110). They require ATP and Mg+2 to be active. 
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B has four different isoforms and has a tryptophan-aspartate repeat which helps in its 
identification. B’ has five isoforms which are all identical in the center region but dif-
ferent in the C and N terminals. B’’ has three isoforms. Different regulatory subunits 
direct the holoenzyme to perform varied functions. For example, binding of B subunit 
to the PP2A complex prevents simian virus40 replication whereas binding of B’’ does 
the opposite. 
PP2Ac (catalytic subunit) is in globular structure, ubiquitously expressed in al-
most all the tissues and is abundant in heart and brain. PP2Ac is conserved from eukar-
yotes to mammals, with 86% sequence match between yeast and humans. It is respon-
sible for the catalytic activity of the enzyme. PP2Ac has two isoforms, alpha and beta, 
which are 97% identical. Both are composed of 309 amino acids and differ only by 8 
amino acids at the N terminal. PP2Ac alpha is found mainly in plasma membrane 
whereas beta isoform is in cytoplasm and nucleus. PP2Ac alpha is more abundant than 
PP2Ac beta because of the high degree of mRNA translation13. Unique feature of 
PP2Ac is that C terminal tail is highly conserved (304TPDYEL309). This tail binds to the 
A and B subunits of the complex. 
1.3.2 REGULATION OF PP2A 
 
 Given the presence of large number of A, B and C subunit isoforms, various 
PP2A complexes are possible.  The combination of the A, B and C subunit isoforms 
affects the activity and specificity of PP2A complexes against a particular substrate. 
Binding and the presence of other regulators can also influence PP2A activity and spec-
ificity14,15. 
PP2A activity is also regulated by post-translational modifications16. Several 
experiments in vivo as well as in vitro showed that phosphorylation on Tyr307 on 
PP2Ac
16
 deactivates PP2Ac by preventing its interaction with the regulatory subunit. 
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Phosphorylation is also reported in a few PP2A regulatory subunits, which altered their 
activity and also substrate specificity.  In addition, carboxyl methylation on the car-
boxyl group of the C-terminal residue of Leu309 increases the activity of PP2Ac by in-
creasing its binding to A and B subunits. Leucine Carboxyl Methyl Transferase 
(LCMT), also known as PP2A-Methyl transferase (PPMT), is responsible for methyla-
tion of PP2Ac, while PP2A Methyl Esterase (PPME) is responsible for PP2Ac de-meth-
ylation.  
1.3.3 INHIBITORS OF PP2A 
 There are two inhibitors which are found to inhibit PP2A which are found 
through in vitro and in vivo experiments which are termed as I1
PP2A and I2
PP2A 16. Many 
small compound found naturally inhibit PP2A. One of them being Okadaic acid which 
is being used in laboratory practices. It also inhibits other phosphatases like pp1 but at 
relatively higher concentrations. Other commercially available inhibitors include calyc-
ulin a, tautomycin, microcystins, cantharidin and endothall.  
1.3.4 ROLE OF PP2A 
  PP2A is found to be involved in many cell signaling pathways, cell cycle reg-
ulation and various other pathways. Experiments conducted by employing phosphatase 
inhibitor Okadaic acid showed that PP2A plays a role in cell cycle regulation (G2/M 
transition). Using Yeast, they presented the role of various B subunit analogues in cell 
cycle, stress response, cytoskeleton organization and morphogenesis. Experiments on 
drosophila showed the importance of PP2A in early embryogenesis and the changes in 
the tissue distribution during its development. Several viral antigens are found to inter-
act with PP2A and prevent the inhibitory role of PP2A in those signaling pathways and 
promote cell proliferation. It is also shown in Xenopus eggs that it involves in initiation 
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of DNA replication. Several experiments showed the involvement of PP2A in termina-
tion of DNA replication, apoptosis, DNA damage response and heat shock response13. 
1.3.5 PP2A IN INSULIN SIGNALING 
   
         Saturated fatty acids like palmitate negatively regulate insulin signaling pathway 
by activating PP2A, which dephosphorylates Akt and ERK1/2. Opposite effect is seen 
with unsaturated fatty acids like oleic acid or linoleic acid17. 
         There are evidences that insulin inactivates PP2A through in vitro and in vivo 
experiments. Also published evidence shows interaction of PP2A with many signaling 
molecules, some of which are involved in insulin signaling pathway. Jian Chen et al 
showed that PP2A is phosphorylated in vitro by the tyrosine kinases which included 
insulin receptors. It is phosphorylated on Tyr307 and this inactivated PP2A16 . 
The effect of insulin on PP2A during myogenesis in rat L6 cells is shown by 
Srinivasan and Begum. They showed that insulin inactivated PP2A in the differentiated 
cells .They also showed that the phosphatase activity decreased relatively with the in-
creased concentrations of insulin and also the incubation time18. 
One of the effects of insulin in skeletal muscle cells is the glycogen synthesis 
through the INS/IRS-1/pkb pathway. Rosanna Cazzolli and associates showed that 
ceramide treatment of C2C12 skeletal myotubes reduced the glycogen synthesis 
through inhibition of phosphorylation on PKB upon insulin stimulation. They proved 
that this inhibition is mediated through activated PP2A  via ceramide and thereby ef-
fecting the glycogen synthesis in the skeletal muscle cells19. 
It is also shown that PP2A has a positive effect on the INS signaling pathway 
by preventing the excessive serine phosphorylation on the IRS-1 which will otherwise 
negatively regulate the pathway. One such serine kinases is ribosomal protein P70 S6K-
1 which is an effector of mTOR. They showed direct Interaction of PP2A with IRS-1 
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in cardiomyocytes protecting IRS-1 from excessive serine phosphorylation. They in-
ferred from their results that PP2A interacts with IRS-1 via mTOR competing for serine 
residues on IRS-1 and thereby deciding the phosphorylation status of IRS-1. Many fac-
tors affect the association, one being the INS stimulation20. 
Only one group conducted experiments on human skeletal muscle where they 
compared ten type II diabetics with ten controls. They showed that upon insulin stimu-
lation, PP2A levels in control subjects reduced when compared to the basal levels but 
not in type II diabetics. They also showed corresponding reduction in glucose disposal, 
glucose oxidation and increase in lipid oxidation21. 
1.4 INSULIN SENSITIVITY; PROTEIN INTERACTIONS AND MASS SPEC-
TROMETRY 
1.4.1 METHODS TO MEASURE INSULIN SENSITIVITY  
There are several methods to measure insulin sensitivity in humans. Hyperinsu-
linemic euglycemic clamp and insulin suppression test are used for direct measurement 
of insulin sensitivity whereas Oral glucose tolerance test and minimal model analysis 
of frequently sampled intravenous glucose tolerance test are considered for indirect 
measurement. There are several other Indices used for quick measurement of insulin 
sensitivity in cases where feasibility is an issue.22 
For settings where insulin sensitivity measurement and maintenance of steady 
state conditions is crucial, hyperinsulinemic euglycemic clamp should be the first 
choice. This technique is also mentioned as a gold standard to assess the action of in-
sulin in vivo23. The action of insulin on the body is measured by the rate of exogenous 
glucose infused to maintain a constant blood glucose concentration. Under conditions 
of hyperinsulinemia, most (>70%) of the infused glucose is used by skeletal muscle. 
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This implies that the index measured during the clamp mainly reflects the skeletal mus-
cle sensitivity to insulin4. 
1.4.2 IMPORTANCE OF PROTEIN-PROTEIN INTERACTIONS 
 
Most of the proteins in vivo act in the form of complexes. These proteins con-
tribute to about 80%. Protein interactions play a very crucial role in various functions 
of the cell, such as gene transcription, signal transduction24, cell cycle regulation, etc. 
Correct formation of these complexes is important for the normal body function. Ab-
normalities in protein-protein interactions cause aberrant cell signals and thereby cause 
diseases. Many protein complexes have been targeted to treat diseases25. Studying the 
interactions will help us to find out the function of the particular target protein which is 
specifically useful in cases of any unidentified protein. It will also enable us to analyze 
the signaling pathways. Protein-protein Interactions have been classified as homo oli-
gomeric /hetero oligomeric based on interaction surface; obligate/non obligate based 
on stability and transient/permanent depending on persistence26 
Protein-protein interactions may result in changes in 
1. Kinetic characteristics of the complexes  
2. Substrate channeling 
3. A new binding site on the complex for other effector molecules  
4. Substrate specificity  
5. Activity of the complex 
6. Downstream events  
Methods to determine protein-protein interactions. Biophysical methods de-
termine these interactions using the structural information of the proteins. These include 
X-ray crystallography, NMR Spectroscopy, fluorescence and atomic force microscopy. 
Direct high throughput methods include yeast two hybrid, affinity purification and mass 
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spectrometry27,28,29. Indirect high throughput methods include gene co-expression and 
synthetic lethality. Computational predictions of the protein-protein interactions have 
also been reported27. Affinity purification coupled with mass spectrometry (AP-MS) is 
widely used for identification of interaction networks28. Affinity purification allows to 
enrich the target protein of interest and its co-interaction partners in a single step, and 
mass spectrometry offers supreme ability to identify proteins from a complex mixture 
in a high throughout fashion28,29.  
1.4.3 MASS SPECTROMETRY 
 
 Mass spectrometry is the most sensitive approach for global identification and 
quantification of proteins, protein-protein interactions, and protein post translational 
modifications30.  The main components of a mass spectrometry instruments, a mass 
spectrometer, include an ion source, a mass analyzer, and a detector30: 
1. Ion source: a device to generate charged particles. Electrospray ionization 
(ESI) and matrix-assisted laser desorption ionization (MALDI) are two com-
monly used ion sources for proteomics studies30. 
2. Mass analyzer: a device to separate the ions based on their mass-to-charge 
ratio, m/z30.  Four common types of analyzers for the proteomic analysis include 
quadruple, Ion trap (quadruple ion trap, linear ion trap), time of flight, and or-
bitrap analyzers30. 
3. Detector: A detector is a device to record either the charge induced when an 
ion hits a surface or the current produced when an ion passes by 30. Two main 
detectors are electron multiplier (charge induced when ions hit a plate) and im-
age current detector (current produced when ions pass) 30. 
 As every wet lab experiment, proteomics studies begin with collecting starting 
material (e.g., tissue, body fluid, cell lysates, etc.) and followed by protein separation 
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(e.g., affinity capture, electrophoresis, liquid chromatography, etc.).  Proteins are 
cleaved into peptides by enzymatic digestion. The most commonly used protease/en-
zyme for this purpose is trypsin due to its well defined specificity, which hydrolyzes 
proteins at the carboxyl side (or "C-terminal side") of the amino acids lysine and argi-
nine.  Since one protein may generate many peptides after trypsin digestion, a tryptic 
digest of a complex mixture of proteins may contain thousands or even millions of 
peptides.  Therefore, the resulting peptides are further separated using a variety of tech-
niques (e.g. affinity capture, liquid chromatography, etc.).  The separated peptides are 
analyzed by mass spectrometry for peptide/protein identification and quantification.   
In the present work, the proteomic approach developed in our laboratory31 was 
applied to investigate PP2Ac interaction partners in human skeletal muscle from over-
weight/obese non-diabetic human participants. I asked following three questions 1). 
Are PP2Ac interaction partners reported in cell culture or animal models indeed interact 
with PP2Ac in human skeletal muscle? 2). Are there new PP2Ac interaction partners in 
human skeletal muscle? 3). Are there insulin responsive PP2Ac interaction partners in 
human skeletal muscle? 
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CHAPTER 2 RESEARCH DESIGN AND METHODS 
Clinical and proteomics studies were carried out similar to those describe31, 
which reported the discovery of new IRS1 interaction partners in human skeletal mus-
cle. The main difference was that PP2Ac Co-immunoprecipitation was used to enrich 
PP2Ac interaction partners in the present work instead of IRS1 Co-immunoprecipita-
tion used in the publication.    
As illustrated in Fig. 3, the approach we used included extensive clinical and 
proteomics data acquisition and data analysis. We first recruited subjects which was 
followed by comprehensive tests to screen them for eligibility. This is followed by hy-
perinsulinemic-euglycemic clamp, procedure to measure insulin sensitivity and muscle 
biopsies are collected. The study was performed in the following order: biopsy homog-
enization; immunoprecipitation of the “bait” protein (PP2Ac), at the endogenous level; 
followed by one dimensional SDS-PAGE to separate co-interaction proteins; in-gel 
trypsin digestion to generate peptide fragments; and HPLC-ESI-MS/MS analysis to 
identify co-immunoprecipitating proteins. Multiple biological comparisons and im-
munoprecipitation of NIgG (as non-specific control) were used for false positive mini-
mization.  Extensive literature searches as well as bioinformatics were used to integrate 
clinical and proteomics data and to identify pathways and functional categories in 
which identified PP2Ac interaction partners were involved.  
2.1 MATERIALS  
2.1.1 REAGENTS 
 
Reagents are from these suppliers: sequencing-grade modified trypsin 
(Promega, Madison, WI); protein A sepharose and iodoacetamide (Sigma, St Louis, 
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MO); C18 ZipTip (Millipore, Billerica, MA); antibody to PP2Ac (Upstate/Millipore, 
Billerica, MA). 
2.1.2 SUBJECTS 
 
A total of 8 overweight/obese non-diabetic volunteers were recruited and took 
part in the study at the C. S. MOTT Clinical Research Center at Wayne State University. 
Written consent was attained from all participants and the   study was explained in detail 
including the indirect benefits and risks.  No one had any significant medical problems, 
and none engaged in any heavy exercise, and they were directed to stop all kinds of 
exercise for at least 2 days prior to the study. Institutional Review Board of Wayne 
State University approved this protocol. 
2.1.3 HYPERINSULINEMIC-EUGLYCEMIC CLAMP WITH MUSCLE BIOP-
SIES 
 A hyperinsulinemic-euglycemic clamp was used to assess insulin sensitivity 
and expose skeletal muscle to insulin in vivo, as previously described31.  Followed by a 
ten hour overnight fast, the study began at approximately 08:30 hours (time -60 
min).Two catheters were placed, one in an antecubital vein, maintained throughout the 
study for infusions of insulin and glucose. The second in a vein in the contra lateral 
arm, which was covered with a heating pad (60°C). The purpose of heating pad is to 
arterialize the venous blood being collected. Blood samples were collected for determi-
nation of plasma glucose concentrations. At approximately 09:00 hours (time −30 min), 
under local anesthesia, a percutaneous needle biopsy of the vastus lateralis muscle was 
performed. These biopsy samples were blotted free of blood, cleaned of connective 
tissue and fat (~30 sec), and then frozen in liquid nitrogen. At 09:30 hours (time 0 min), 
continuous human insulin (Humulin R; Eli Lilly, Indianapolis, IN) infusion was begun 
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at a rate of 80 mU m-2 minute-1, and continued for 120 min. Plasma glucose was meas-
ured at 5-min intervals throughout the clamp.  Euglycemia was maintained at 90 mg/dl 
by variable infusion of 20% d-glucose.  Another biopsy is taken at 11:30 hours (time 
120 minutes) in the contralateral leg.   
Plasma insulin concentration was calculated using the ALPCO Insulin ELISA 
Jumbo (Alpco Diagnostics, Salem, NH). 
2.2 PROTEOMICS SAMPLE PREPARATION AND ANALYSIS 
2.2.1 SAMPLE PREPARATION 
 
 Biopsies were homogenized and processed as described31-33. The lysate pro-
teins were precleared with NIgG followed by PP2AC immunoprecipitation. The co-
immunoprecipitates were resolved on one dimensional SDS-PAGE, which is followed 
by in-gel trypsin digestion, peptide enrichment, and HPLC-ESI-MS/MS analysis using 
a LTQ-Orbitrap Elite as described31. Peptides/protein identification and quantification 
were performed using the MaxQuant software. It is one of the most prevalent quantita-
tive proteomics software34. Using this, peak areas for each protein were obtained by 
selecting the option for label-free quantification (LFQ). Only those proteins with a min-
imum of 2 unique peptides and with false discovery rate (FDR) at 0.01 were considered. 
In total, 2057 proteins were identified in the 16 muscle biopsies using HPLC-ESI-
MS/MS. 
To be considered as a PP2Ac interaction partner, a protein has to additionally 
pass these following criteria: 1). with an enrichment ratio >10; 2). Identified with LFQ 
peak area (PA) in more than half of the PP2Ac IP (i.e. >8 biopsies used). The enrich-
ment ratio was calculated as follows: 1st, PA for a protein identified in a gel lane was 
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normalized against the sum of the peak areas for all proteins identified in the same gel 
lane to obtain normalized ratio for individual protein, Norm:i, 
Norm: 𝑖 =
PA𝑖
∑ PA𝑖n1
   
Then, the average of normalized ratio for each protein in the IRS1 co-immunopre-
cipitates, Average_Norm:i_IRS1, as well as the average of normalized ratio for the 
same protein in the NIgG co-immunoprecipitates, Average_Norm:i_NIgG, were ob-
tained. Finally, Average_Norm:i_PP2Ac was divided by Average_Norm:i_NIgG, 
which gives the enrichment ratio for each protein.  
Enrichment_Ratio: 𝑖 =
Average_Norm: 𝑖_PP2Ac
Average_Norm: 𝑖_NIgG
  
Proteins exclusively detected in the PP2Ac immunoprecipitates were identified 
as we used NIgG as a control. Nevertheless, this will give rise to false negatives. But 
due to the high sensitivity of our method, trace amounts of a protein will be detected 
even it was non-specifically absorbed on the NIgG beads, it may be identified with 
minimum 2 unique peptides with FDR at 0.01. However, if a protein is true component 
of the PP2Ac complex, higher peak area will be assigned to this protein in the PP2Ac 
sample than in the NIgG sample.  
 To determine the relative quantities of PP2Ac interaction partners in human 
skeletal muscle biopsies before and after insulin infusion in vivo, the PA for each pro-
tein identified in a specific biopsy was normalized against the PA for PP2Ac identified 
in the same biopsy, which results in Norm:j.  
Norm: 𝑗 =
PA𝑗
PA_PP2Ac
   
The normalization strategy is widely used in proteomics studies involving pro-
tein-protein interactions35, and uses similar concept as in western blotting, where the 
signal for an interaction protein is normalized against that for the protein serving as the 
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“bait.” The normalized peak area for each PP2Ac interaction partner, Norm:j, was con-
verted to log2 form and compared within the group to assess effects of insulin on pro-
tein-protein interactions involving PP2Ac.  
2.2.2 STATISTICAL ANALYSIS 
 
            Although a large number of proteins were assigned in at least one of 16 biop-
sies that were studied, various filters narrowed the number of proteins that were used 
in comparisons among groups as described above.  This approach is diagrammed in 
Fig. 5.  To assess the effects of insulin within group, statistical significance was calcu-
lated applying paired t tests.  Changes were statistically significant at p<0.05. 
Pathway analysis on PP2Ac interaction partners was performed using Ingenuity 
Pathway Analysis (Ingenuity Systems, Inc., Redwood City, CA), which is widely used 
and contain biological and chemical interactions and functional annotations created by 
manual curation of the scientific literature36.  A pathway was considered significantly 
enriched if the p-value for that pathway was less than 0.01 and contained at least 4 
identified PP2Ac partners.   
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CHAPTER 3 RESULTS 
Clinical characteristics of the eight overweight/obese control subjects.  Table 4 
lists the clinical characteristics for the subjects.  
3.1 PP2AC INTERACTION PARTNERS IN SKELETAL MUSCLE FROM 
OVERWEIGHT/OBESE HUMAN PARTICIPANTS  
          PP2Acα and PP2Acβ were detected in PP2Ac immunoprecipitates from all 16 
biopsies used for the study, but were not detected at all in the NIgG immunoprecipitates. 
In total, 186 proteins met the criteria for classification as PP2Ac interaction partners 
(Figure 5 and Table 4). Note that PP2Ac interaction partners listed in Table 5 may in-
volve both direct and indirect partners.  
Table 4 lists the 186 PP2Ac interaction partners with fold changes between bi-
opsies obtained before and after insulin infusion in overweight/obese human partici-
pants. Among these 186 PP2Ac interaction partners, 14 partners were previously re-
ported while 172 were novel.  The known PP2Ac interaction partners included AMPK, 
CCT2, CCT3, CCT4, CCT5, CCT6A, CCT8, IGBP1, PPME1, PPP2R1A, PPP2R2A, 
Rpn2, TCP1, TUBA8. 
Ingenuity pathway analysis on the 186 PP2Ac interaction partners and PP2Ac 
suggested various pathways significantly enriched compared to the whole genome 
background, such as mTOR and MAPK signaling (Figure 6 and Table 5).  One of the 
significantly enriched pathway, mTOR signaling, was illustrated in Figure 7 
We also performed network analysis using Ingenuity pathway analysis for the 
186 PP2Ac interaction partners and PP2Ac to illustrate how these partners can be in-
terrelated. Figure 6 shows the network with the highest score and highest number of 
interaction partners identified in this study.  
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3.2 INSULIN-RESPONSIVE PP2AC INTERACTION PARTNERS IN SKELE-
TAL MUSCLE FROM OVERWEIGHT/OBESE HUMAN PARTICIPANTS 
          Upon insulin infusion in vivo, 17 PP2Ac interaction partners showed significant 
difference in their association with PP2Ac (P<0.05). Among them, ten PP2Ac interac-
tion partners showed decreased interaction (Table 6) and the remaining seven showed 
increased interaction (Table 7). 
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CHAPTER 4 DISCUSSION 
4.1 PP2AC INTERACTION PARTNERS IN SKELETAL MUSCLE FROM 
OVERWEIGHT/OBESE HUMAN PARTICIPANTS        
       Using the proteomics approach for protein-protein interactions developed in our 
laboratory31, we have identified 186 PP2Ac interaction partners in skeletal muscle form 
8 overweight/obese human participants, which represents the largest PP2Ac interaction 
network in humans to date.  Among them, 14 were known PP2Ac interaction partners 
while 172 were novel (Table 4).    
       Among these 14 PP2Ac interaction partners, PPP2R1A and PPP2R2A are ‘A’ sub-
unit alpha isoform and ‘B’ subunit alpha isoform of the PP2A complex, respectively. 
PPME1 is protein methylesterase, which catalyzes the demethylation of PP2A on leu-
cine309. As mentioned in the Introduction, demethylation of the catalytic subunit at 
this site may decrease the stability of the PP2Ac complex and subsequent PP2A activ-
ity. When PP2Ac is not exit as a complex, it will be directed for proteasome degradation 
by the E3 ubiquitin ligase. IGBP1 also known as alpha4, binds to catalytic subunit 
thereby stabilizing and preventing it from the degradation37. CCT2, CCT3, CCT4, 
CCT5, CCT6A, CCT8, TCP1 are chaperone proteins. All the translated proteins need 
to be folded properly in order to achieve the tertiary structure. Sometimes, they can be 
misfolded. These misfolded or unfolded proteins can aggregate to form lethal com-
plexes. The function of these chaperones is to correct the partially folded or misfolded 
proteins using ATP as source of energy38. Rpn2 is Ribophorin II, which is subunit of 
the enzyme oligosaccharyltransferase complex. This enzyme transfers glycosyl group 
from a lipid molecule to asparagine of Asn-x-Thr/Ser sequence. The enzyme is specific 
to the membrane of Rough endoplasmic reticulum. Glycosylation is a post translational 
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modification of the proteins. This modification of nascent proteins is important some-
times in the proper folding of the proteins39. TUBA8 belongs to alpha tubulin protein 
family that heterodimerizes and forms microtubule40.   AMPK is a protein kinase which 
is activated in response to altered energy levels in the cell. PP2A has been shown to be 
able to dephosphorylate AMPK41. Higher ATP levels reduce the activity of AMPK. 
When the AMP levels rise, ATP is exchanged for AMP and this activates AMPK. 
AMPK comprises of alpha beta and gamma subunits. Alpha and beta having two 
isoforms and gamma subunit with three isoforms. Identified isoforms are PRKAG1 
(gamma 1), PRKAA2 (alpha 2), PRKAB2 (beta 2). PRKAG1 is ubiquitously expressed 
whereas PRKAA2 and PRKAB2 are found abundant in skeletal muscle cells. It is 
known to have important role in skeletal muscle insulin sensitivity42. In skeletal muscle, 
activation of AMPK will cause fatty acid and glucose oxidation. It also plays a role in 
activation of GLUT4 transporters which are responsible for uptake of glucose upon 
recruitment to plasma membrane. Plays a role in glycogen metabolism43. Activation is 
carried out by phosphorylation of AMPK at various serine and threonine sites. It is 
phosphorylated by minimum three kinases. Its binding to PP2Ac may change the phos-
phorylation status of this kinase and thereby its activation or inactivation. Since denovo 
AMP synthesis will activate AMPK, experiments were conducted using rat hepatocytes 
to see if altering the activity of enzymes involved in purine biosynthesis will improve 
insulin sensitivity. They found that abundant adenosuccinate lyase (ADSL) can lead to 
increased AMP production. There by AMPK activation and improved insulin sensitiv-
ity44. Both ADSL and AMPK are found as potential interaction partners. 
      mTOR pathway has great impact on the cell growth and metabolism. It regulates 
protein biosynthesis, lipid synthesis, mitochondrial biogenesis and metabolism. Previ-
ous reports show that PP2A is down regulated by mTOR, and degradation of IRS1 by 
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mTOR is achieved through inhibition of PP2A45. In the present work, we detected tran-
scription factors (elf3 and elf4G) that regulate protein synthesis as partners of PP2Ac. 
Growth factors like insulin stimulate mTOR by increased phosphorylation of TSC2 
protein by kinases like PKB, ERK1/2 and RSK1. This TSC2 phosphorylation leads to 
inactivation of TSC1/2 and there by activation of Mtor. AMPK is activated in response 
to low energy levels. This activated AMPK phosphorylates and reduce the activity of 
TSC2 and thereby reduce mTOR activation46. RSK1 and AMPK regulate the mTOR 
pathway mainly by phosphorylation events by kinases and dephosphorylation events 
possibly regulated by PP2A.   
4.2 INSULIN-RESPONSIVE PP2AC INTERACTION PARTNERS IN SKELE-
TAL MUSCLE FROM OVERWEIGHT/OBESE HUMAN PARTICIPANTS  
      Upon insulin infusion in vivo, 10 PP2Ac interaction partners had a decreased asso-
ciation with PP2Ac (P<0.05, Table 6).  Among them, 5 were involved in vesicle traffic, 
including Archain1, Adp-ribosylation factor 4, Coatomer protein complex 
subunit alpha, Sec1 family domain containing 1, Vesicle amine transport 1. 
Archain1, also known as coatomer protein complex subunit delta, and COPA, which is 
coatomer protein complex subunit alpha, are coat proteins. They have important func-
tion in transporting proteins between Golgi apparatus and Endoplasmic reticulum. They 
are also involved in budding of the vesicles from the Golgi membrane. These coat pro-
teins require ARF proteins for this function47. ARF proteins are GTP-binding proteins 
which upon activation at the membrane recruit these coat proteins and thereby aiding 
these vesicles to bud from Golgi apparatus48. ARF4 is involved in insulin mediated 
activation of Phospholipase D and also Vesicle trafficking. SCFD1, Sec1 family do-
main containing 1, is also involved in vesicle transport between Golgi and Endoplasmic 
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reticulum.  VAT1, vesicle amine transport 1, is found to be involved in regulation of 
mitochondrial fusion. It is shown to have ATPase activity. 
      Glycogenin is a primer for the glycogen synthesis which is further extended by gly-
cogen synthase and glycogen branching enzyme49.  
      Proteasome 26S subunit, ATPase, 3 is part of the proteasome complex which de-
grades proteins that are tagged with ubiquitin50. Ubiquitin proteasome plays an im-
portant role in regulation of Insulin signaling pathway by ubiquitination and subsequent 
degradation of Insulin Receptor Substrate, GLUT1 and GLUT451.  
      STAT3 is a transcription factor which upon activation by any growth factor will 
cause transcription of appropriate genes. It was showed that phosphorylated STAT3 
amounts are increased by two fold in overweight T2D compared to overweight controls. 
STAT3 is also shown to contribute to insulin resistance in various tissues like liver and 
smooth muscle52.  
      Upon insulin infusion in vivo, 7 PP2Ac interaction partners had an increased 
association with PP2Ac (P<0.05, Table 6).  ATP synthase beta polypeptide and dihy-
drolipogenase are mitochondrial proteins. ATP synthase beta is one of the subunits of 
the catalytic core of ATP synthase enzyme. This enzyme catalyzes the formation of 
ATP from ADP in the mitochondria53. Mitochondrial dysfunction is linked to obesity 
and Type II Diabetes. Experiments were conducted on human skeletal muscle compar-
ing the phosphorylation of this protein between basal and insulin stimulated biopsies of 
lean, obese and T2D. The amount of ATP synthase in basal biopsies is found to be 
decreased in obese and T2D compared to lean. They found abnormal phosphorylation 
sites in obese and T2D54. As a partner of PP2Ac, It is possible that phosphorylation and 
dephosphorylation of this protein is regulated by PP2A which thereby influences Insu-
lin signaling and insulin resistance.  
23 
 
 
      PGM1, phosphoglucomutase-1, is involved in the breakdown and formation of glu-
cose, Conversion of glucose 6 phosphate to glucose 1 phosphate and vice versa55.  
      NT5C3, 5’ Nucleotidase, breaks down nucleotides to nucleosides and phosphate.  
      ADSL, Adenylsuccinate lyase, catalyzes two steps in de novo Adenosine Mono 
Phosphate synthesis.  
      PPP1R7 is a regulatory subunit of protein phosphatase 1 (PP1). PP1 also belongs to 
phosphoprotein phosphatase family, and is also a serine/threonine protein phospha-
tase56.        
      PPP2R2A is one of the regulatory subunits of PP2A. Binding of this subunit cata-
lyzed many dephosphorylation events involved in cell cycle regulation57, DNA repair58, 
TGFβ signaling59, Wnt signaling60 and diseases like cancer. In islet β cells, presence of 
this subunit directed PP2A to dephosphorylate FOXO1 under oxidative stress condi-
tions61. Considering the role of regulatory subunits in regulating the localization and 
specificity of PP2A, unveiling its role in skeletal muscle may reveal important infor-
mation in specific to skeletal muscle. 
4.3 SUMMARY 
In the present work, PP2Ac was found to interact with 186 protein partners 
either directly or indirectly in human skeletal muscle. This is the largest PP2Ac 
interaction partner network found in humans till date.  Moreover, seventeen insulin-
responsive PP2Ac interaction partners in skeletal muscle were identified in 
overweeight/obesse human subjects. Validating some of the important partners 
(partners that may directly or indirectly effect the insulin signaling pathway) would be 
the next step. In addition, comparison with lean and T2D participants will discover the 
differences in the PP2Ac partners among the 3 groups.  This information will help us 
understand the role of PP2A in the development of inuslin resistance and T2D. 
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Figure 1. Insulin signaling pathway showing the signaling molecules involved 
and various effects seen62 
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Figure 2. Diagrammatic representation of heterotrimeric PP2A complex 
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   Figure 3.  Main steps in mass spectrometry-based proteomics studies 
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       Figure 4. Clinical and proteomics data acquisition and data analysis 
 
 
 
 
Subject recruitment 
(e.g., advertisement, phone screening, scheduling, etc.) 
Comprehensive screening tests 
(e.g., OGTT, blood chemistry, BMI, ECG, etc.) 
In-patient clinical testing 
(e.g., muscle biopsies, hyperinsulinemic-euglycemic clamp) 
Muscle biopsies from overweight/obese (n=7): Basal & 2h 
16 biopsies 
5-10mg protein lysate 
NIgG Co-IP & PP2Ac Co-IP 
HPLC-ESI-MS/MS 
LTQ-Orbitrap Elite 
MaxQuant: Protein identification & quantification 
Ingenuity: Pathway & network analysis 
1D-SDS-PAGE 
Trypsin in-gel digestion 
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Figure 5. Proteomics data analysis 
 
 
 
 
 
 
 
 
Proteins identified with minimum 2 unique peptides with FDR at 0.01 in at least one 
PP2Ac IP after excluding common contaminants?      (2057 proteins, including 
PPP2CA/B) 
Identified with LFQ peak area (PA) in more than half (e.g., > 8 out of 16) PP2Ac 
IP samples? 
(188 proteins, including PPP2CA/B) 
Enrichment ratio for each protein determined.  Enrichment ratio for a protein > 
10 (PP2Ac vs NIgG IP)? 
(586 proteins, including PPP2CA/B)  
Normalized PA for PP2Ac interaction part-
ners determined 
P<0.05 by paired t tests? 
(17 proteins) 
With a fold change over basal greater than 1.5 (i.e., 1.5 fold increase) or  
less than 0.67 (i.e., 1.5 fold decrease) Insulin vs. Basal? 
(115 proteins) 
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Figure 6. Significantly enriched pathways for the 186 PP2Ac interaction partners 
and PP2Ac in human skeletal muscle.  The number of PP2Ac interaction partners 
identified in this study in a particular pathway is beside the bar. 
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Figure 7.  The significantly enriched pathway, mTOR signaling, for the 186 
PP2Ac interaction partners and PP2Ac. PP2Ac interaction partners were 
highlighted in yellow and PP2A was highlighted in purple 
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Figure 8. Network pathway obtained from Ingenuity Pathway Analysis Pathway 
obtained using 70 molecules per network and the one assigned with highest score 
is taken; shows 45 interaction partners; target protein PP2Ac (in purple) proteins 
without any change (in yellow), which showed significant decrease (in red) and 
significant increase (in green) upon insulin stimulation 
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Table 1 showing the various isoforms of PP2A subunits, their cellular and sub-
cellular distribution8. HE: high expression 
Subunit Gene Iso-
form 
Other name Normal tissue 
distribution 
Subcellular 
distribution 
Scaffold (A) PPP2R1A Α PR65α, 
PP2A-Aα 
Ubiquitously ex-
pressed and 
highly expressed 
in ovary (oogene-
sis) 
Cytosol 
  PPP2R1B Β PR65β, PP2A-
Aβ 
Ubiquitously ex-
pressed and 
highly expressed 
in ovary (oogene-
sis) 
Cytosol 
Catalytic (C) PPP2CA Α PP2Acα Brain and heart 
(HE). Present in 
skeletal muscle21 
Cytoplasm 
and nucleus 
  PPP2CB Β PP2Acβ Brain and heart 
(HE) 
Cytoplasm 
and nucleus 
Regulatory 
(B) 
PPP2R2A Α PR55α, 
PP2ABα 
Widely distrib-
uted in all tissues  
Membranes, 
cytoplasm, 
microtubules 
nucleus. 
Golgi com-
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plex, endo-
plasmic retic-
ulum and 
neurofila-
ments 
  PPP2R2B Β PR55β, 
PP2ABβ 
Brain and testis 
(HE) 
Cytosol 
  PPP2R2C Γ PR55γ, 
PP2ABγ 
Brain (SE)  Mainly in 
Cytoskeletal 
fraction 
  PPP2R2D Δ PR55δ, 
PP2ABδ 
Wide spread dis-
tribution in tis-
sues, Testis (HE) 
Cytosol 
Regulatory 
(B′) 
PPP2R5A Α PR56/61α, 
PP2AB′α 
Cardiac tissues 
and skeletal mus-
cles63 (HE) 
Cytoplasm 
  PPP2R5B Β PR56/61β, 
PP2AB′β 
Brain (HE) Cytoplasm 
  PPP2R5C Γ1, 2,3 PR56/61γ, 
PP2AB′γ 
Cardiac tissues 
and skeletal mus-
cles64 (HE) 
Cytoplasm 
and nucleus 
  PPP2R5D Δ PR56/61δ, 
PP2AB′δ 
Primarily exist in 
brain 
Cytoplasm, 
nucleus, mi-
tochondria, 
microsomes 
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  PPP2R5E Ε PR56/61ε, 
PP2AB′ε 
Primarily exist in 
brain  
Cytoplasm 
Regulatory 
(B″) 
PPP2R3A Α PR130, B″α1 Brain (HE), heart, 
lung, kidney and 
muscle65 
Centrosome 
and Golgi 
complex 
  PPP2R3A Α PR72, B″α2 Heart (HE) and 
skeletal muscle65 
Cytosol and 
nucleus 
  PPP2R3B Β PR70, PR48, 
B″β 
Placenta  Nucleus 
  PPP2R3C Γ G5PR, G4-1 During develop-
mental process 
expressed in fetal 
brain 
Nucleus 
  PPP2R3D Δ PR59, B″δ Cardiac tissue, 
kidney and lungs  
Nucleus 
Regulatory 
(B″′) 
STRN   Striatin, 
PR110 
Brain  Membrane 
and cyto-
plasm 
  STRN3   SG2NA Neurons  Nucleus 
  PPP2R4   PTPA, PR53 Widely expressed Cytosol, nu-
cleus 
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Table 2 showing various inhibitors of PP2A including their sources and specificity 
to different phosphatases 6. 
Inhibitor Source Inhibitory        potency 
Okadaic acid Dinoflagellates PP2A ∼ PP4 > PP1 ∼ 
PP5 >>> PP2B∗ 
Dinophysistoxin-1 Dinoflagellates PP2A > PP1 >>> PP2B 
Microcystins Cyanobacteria PP2A ∼ PP1 >>> PP2B 
Nodularins/Motuporin Cyanobacteria PP2A ∼ PP1 >>> PP2B 
Calyculin A Isolated from marine sponges PP2A > PP1 >>> PP2B 
Tautomycin Streptomyces spiroventricilla-
tus 
PP1 > PP2A >>> PP2B 
Cantharidin Blister beetles PP2A > PP1 >>> PP2B 
Endothall Synthetic compound PP2A > PP1 >>> PP2B 
Fostriecin Streptomyces pul-
veraceussubsp. Fostreus 
PP2A ∼ PP4∗ 
TF-23A Isolated from marine red alga PP2A 
Cytostatin Streptomyces sp. MJ654-NF4 PP2A 
I1
PP2A Cellular inhibitor PP2A 
I2
PP2A (SET, PHAP-II, 
TAF-1β) 
Cellular inhibitor PP2A 
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Table 3. Clinical characteristics for the 8 overweight/obese participants in the 
PP2Ac interaction partner study. Results were shown as mean ± SEM.   
Gender (M/F) (4/4) 
Age (years) 42.0 ± 3.0 
BMI (kg/m
2
) 31.3 ± 01.3 
2h OGTT Glucose (mg/dl) 115.2 ± 7.8 
HBA1c (%) 5.5 ± 0.1 
Fasting plasma glucose (mg/dl) 92.1 ± 3.5 
Fasting plasma insulin (pmol/l) 29.0 ± 5.1 
M-value (mg/kg/min) 5.8 ± 0.6 
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Table 4. The 186 proteins/ protein groups met the 2 rigorous criteria (See Methods 
for details) for classification as PP2Ac interaction partners in human skeletal mus-
cle. # indicating previously identified PP2A partners. 
ABHD14B Abhydrolase domain containing 14B 
ACAD8 Acyl-coa dehydrogenase family, member 8 
ACADM Acyl-coa dehydrogenase, C-4 to C-12 straight chain 
ACADS Acyl-coa dehydrogenase, C-2 to C-3 short chain 
ACADSB Acyl-coa dehydrogenase, short/branched chain 
ACOT9 Acyl-coa thioesterase 9 
ACP1 Acid phosphatase 1, soluble 
ACTR1B ARP1 Actin-related protein 1 homolog B, centractin beta (yeast) 
ADPRHL1 ADP-ribosylhydrolase like 1 
ADSL Adenylosuccinate lyase 
ADSSL1 Adenylosuccinate synthase like 1 
ALDH6A1 Aldehyde dehydrogenase 6 family, member A1 
ANKRD2 Ankyrin repeat domain 2 (stretch responsive muscle) 
APOL2 Apolipoprotein L, 2 
ARCN1 Archain 1 
ARF4 ADP-ribosylation factor 4 
ART3 ADP-ribosyltransferase 3 
ASNA1 ArsA Arsenite transporter, ATP-binding, homolog 1 (bacterial) 
ATP5A1 ATP synthase, H+ transporting, mitochondrial F1 complex, alpha 
subunit 1, cardiac muscle 
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ATP5B ATP synthase, H+ transporting, mitochondrial F1 complex, beta pol-
ypeptide 
ATP6V1B2 ATPase, H+ transporting, lysosomal 56/58kDa, V1 subunit B2 
ATP6V1E1 ATPase, H+ transporting, lysosomal 31kDa, V1 subunit E1 
BZW2 Basic leucine zipper and W2 domains 2 
CAMK2D Calcium/calmodulin-dependent protein kinase II delta 
CAMK2G Calcium/calmodulin-dependent protein kinase II gamma 
CARM1 Coactivator-associated arginine methyltransferase 1 
CCDC6 Coiled-coil domain containing 6 
CCT2# Chaperonin containing TCP1, subunit 2 (beta) 
CCT3# Chaperonin containing TCP1, subunit 3 (gamma) 
CCT4# Chaperonin containing TCP1, subunit 4 (delta) 
CCT5# Chaperonin containing TCP1, subunit 5 (epsilon) 
CCT6A# Chaperonin containing TCP1, subunit 6A (zeta 1) 
CCT8# Chaperonin containing TCP1, subunit 8 (theta) 
CD59 CD59 molecule, complement regulatory protein 
CDC37 Cell division cycle 37 
CECR5 Cat eye syndrome chromosome region, candidate 5 
CKM Creatine kinase, muscle 
CKMT2 Creatine kinase, mitochondrial 2 (sarcomeric) 
COPA Coatomer protein complex, subunit alpha 
COPS3 COP9 signalosome subunit 3 
COQ9 Coenzyme Q9 
CRBN Cereblon 
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CRYM Crystallin, mu 
CS Citrate synthase 
CUL2 Cullin 2 
DARS Aspartyl-trna synthetase 
DCTN2 Dynactin 2 (p50) 
DDX3X DEAD (Asp-Glu-Ala-Asp) box helicase 3, X-linked 
DDX3Y DEAD (Asp-Glu-Ala-Asp) box helicase 3, Y-linked 
DDX6 DEAD (Asp-Glu-Ala-Asp) box helicase 6 
DHRS7B Dehydrogenase/reductase (SDR family) member 7B 
DIABLO Diablo, IAP-binding mitochondrial protein 
DLD Dihydrolipoamide dehydrogenase 
DLST Dihydrolipoamide S-succinyltransferase (E2 component of 2-oxo-
glutarate complex) 
DNAJA2 Dnaj (Hsp40) homolog, subfamily A, member 2 
DNAJC7 Dnaj (Hsp40) homolog, subfamily C, member 7 
DNM2 Dynamin 2 
DPYSL3 Dihydropyrimidinase-like 3 
EARS2 Glutamyl-trna synthetase 2, mitochondrial 
ECHS1 Enoyl coa hydratase, short chain, 1, mitochondrial 
EHD2 EH-domain containing 2 
EIF2S3 Eukaryotic translation initiation factor 2, subunit 3 gamma, 52kda 
EIF3J Eukaryotic translation initiation factor 3, subunit J 
EIF3L Eukaryotic translation initiation factor 3, subunit L 
EIF4G1 Eukaryotic translation initiation factor 4 gamma, 1 
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ENDOD1 Endonuclease domain containing 1 
FAHD1 Fumarylacetoacetate hydrolase domain containing 1 
FGB Fibrinogen beta chain 
FH Fumarate hydratase 
FLNB Filamin b, beta 
GCDH Glutaryl-coa dehydrogenase 
GDI2 GDP dissociation inhibitor 2 
GFPT1 Glutamine--fructose-6-phosphate transaminase 1 
GMPPB GDP-mannose pyrophosphorylase B 
GPD1L Glycerol-3-phosphate dehydrogenase 1-like 
GPT2 Glutamic pyruvate transaminase (alanine aminotransferase) 2 
GYG1 Glycogenin 1 
HAGH Hydroxyacylglutathione hydrolase 
HSD17B4 Hydroxysteroid (17-beta) dehydrogenase 4 
HSD17B8 Hydroxysteroid (17-beta) dehydrogenase 8 
HSP90AB1 Heat shock protein 90kda alpha (cytosolic), class B member 1 
IARS2 Isoleucyl-trna synthetase 2, mitochondrial 
IDH3B Isocitrate dehydrogenase 3 (NAD+) beta 
IGBP1# Immunoglobulin (CD79A) binding protein 1 
KLC4 Kinesin light chain 4 
KLHL31 Kelch-like family member 31 
KLHL40 Kelch-like family member 40 
KPNA1 Karyopherin alpha 1 (importin alpha 5) 
KPNA3 Karyopherin alpha 3 (importin alpha 4) 
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KPNA4 Karyopherin alpha 4 (importin alpha 3) 
LDHD Lactate dehydrogenase D 
LMCD1 LIM and cysteine-rich domains 1 
LYPLAL1 Lysophospholipase-like 1 
MAML3 Mastermind-like 3 (Drosophila) 
MAOB Monoamine oxidase B 
MAP2K6 Mitogen-activated protein kinase 6 
MAPRE2 Microtubule-associated protein, RP/EB family, member 2 
MURC Muscle-related coiled-coil protein 
MYH11 Myosin, heavy chain 11, smooth muscle 
MYL10 Myosin, light chain 10, regulatory 
MYL2 Myosin, light chain 2, regulatory, cardiac, slow 
MYL6 Myosin, light chain 6, alkali, smooth muscle and non-muscle 
MYL6B Myosin, light chain 6B, alkali, smooth muscle and non-muscle 
NAMPT Nicotinamide phosphoribosyltransferase 
NAP1L4 Nucleosome assembly protein 1-like 4 
NDRG2 NDRG family member 2 
NDUFS8 NADH dehydrogenase (ubiquinone) Fe-S protein 8, 23kDa (NADH-
coenzyme Q reductase) 
NEK7 NIMA-related kinase 7 
NOL3 Nucleolar protein 3 (apoptosis repressor with CARD domain) 
NT5C3A 5'-nucleotidase, cytosolic IIIA 
P4HB Prolyl 4-hydroxylase, beta polypeptide 
PACSIN3 Protein kinase C and casein kinase substrate in neurons 3 
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PCBP2 Poly(rc) binding protein 2 
PCBP3 Poly(rc) binding protein 3 
PCTP Phosphatidylcholine transfer protein 
PCYOX1 Prenylcysteine oxidase 1 
PDHA1 Pyruvate dehydrogenase (lipoamide) alpha 1 
PDHX Pyruvate dehydrogenase complex, component X 
PDIA6 Protein disulfide isomerase family A, member 6 
PDK2 Pyruvate dehydrogenase kinase, isozyme 2 
PGK1 Phosphoglycerate kinase 1 
PGM1 Phosphoglucomutase 1 
PLIN2 Perilipin 2 
PPME1# Protein phosphatase methylesterase 1 
PPP1R7 Protein phosphatase 1, regulatory subunit 7 
PPP2CA Protein phosphatase 2, catalytic subunit, alpha isozyme 
PPP2CB Protein phosphatase 2, catalytic subunit, beta isozyme 
PPP2R1A# Protein phosphatase 2, regulatory subunit A, alpha 
PPP2R2A# Protein phosphatase 2, regulatory subunit B, alpha 
PPP3CB Protein phosphatase 3, catalytic subunit, beta isozyme 
PPP4C Protein phosphatase 4, catalytic subunit 
PPP4R2 Protein phosphatase 4, regulatory subunit 2 
PRKAA2# Protein kinase, AMP-activated, alpha 2 catalytic subunit 
PRKAB2# Protein kinase, AMP-activated, beta 2 non-catalytic subunit 
PRKAG1# Protein kinase, AMP-activated, gamma 1 non-catalytic subunit 
PRKAR1A Protein kinase, cAMP-dependent, regulatory, type I, alpha 
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PSMA4&6 Proteasome (prosome, macropain) subunit, alpha type, 4 and 6 
PSMA6 Proteasome (prosome, macropain) subunit, alpha type, 6 
PSMB3;6 Proteasome (prosome, macropain) subunit, beta type, 3;6 
PSMC3;5 Proteasome (prosome, macropain) 26S subunit, atpase, 3;5 
PSMD11 Proteasome (prosome, macropain) 26S subunit, non-atpase, 11 
PTGR1 Prostaglandin reductase 1 
RAB14 RAB14, member RAS oncogene family 
RAB1B RAB1B, member RAS oncogene family 
RAB6A RAB6A, member RAS oncogene family 
RAB6B RAB6B, member RAS oncogene family 
RDH13 Retinol dehydrogenase 13 (all-trans/9-cis) 
REEP5 Receptor accessory protein 5 
RNH1 Ribonuclease/angiogenin inhibitor 1 
RPL11 Ribosomal protein L11 
RPN2# Ribophorin II 
RPS6KA3 Ribosomal protein S6 kinase, 90kda, polypeptide 3 
RRAGA Ras-related GTP binding A 
RRAGB Ras-related GTP binding B 
RRM2B Ribonucleotide reductase M2 B (TP53 inducible) 
RTN3 Reticulon 3 
SCFD1 Sec1 family domain containing 1 
SCPEP1 Serine carboxypeptidase 1 
SH3GLB1 SH3-domain GRB2-like endophilin B1 
SMTNL2 Smoothelin-like 2 
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SMYD1 SET and MYND domain containing 1 
SSBP1 Single-stranded DNA binding protein 1, mitochondrial 
STAC3 SH3 and cysteine rich domain 3 
STARD7 StAR-related lipid transfer (START) domain containing 7 
STAT3 Signal transducer and activator of transcription 3  
TBRG4 Transforming growth factor beta regulator 4 
TCP1# T-complex 1 
TIMM44 Translocase of inner mitochondrial membrane 44 homolog  
TMEM109 Transmembrane protein 109 
TMEM143 Transmembrane protein 143 
TOM1 Target of myb1 (chicken) 
TPM1 Tropomyosin 1 (alpha) 
TRIM54 Tripartite motif containing 54 
TRIM72 Tripartite motif containing 72, E3 ubiquitin protein ligase 
TUBA4A;8# Tubulin, alpha 4a;8 
TUBB Tubulin, beta class I 
TUBB2A;2
B 
Tubulin, beta 2A class iia; 2B class iib 
TUBB4A Tubulin, beta 4A class Iva 
TUBB6 Tubulin, beta 6 class V 
TUBB8 Tubulin, beta 8 class VIII 
UBAC1 UBA domain containing 1 
UBQLN2 Ubiquilin 2 
UGP2 UDP-glucose pyrophosphorylase 2 
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UQCRFS1 Ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1 
USP14 Ubiquitin specific peptidase 14 (trna-guanine transglycosylase) 
VAT1 Vesicle amine transport 1 
VPS25 Vacuolar protein sorting 25 homolog (S. Cerevisiae) 
VTA1 Vesicle (multivesicular body) trafficking 1 
WARS Tryptophanyl-trna synthetase 
ZADH2 Zinc binding alcohol dehydrogenase domain containing 2 
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Table 5. Significantly enriched pathways for the PP2Ac interaction partners iden-
tified in the study revealed by Ingenuity Pathways Analysis. 
In
g
en
u
it
y
 C
a
n
o
n
ic
a
l 
P
a
th
-
w
a
y
s 
-l
o
g
(p
-v
a
lu
e)
 
G
en
e 
N
a
m
es
 
N
u
m
b
er
 o
f 
id
en
ti
fi
ed
 
P
P
2
A
c 
 
in
te
ra
ct
io
n
 p
a
rt
n
er
s 
in
 t
h
e 
st
u
d
y
 
Epithelial Ad-
herens Junction 
Signaling 
7.61 
 
TUBB6, TUBA8, MYL2, MYL6, 
TUBB8, MYL6B, TUBB2A, 
TUBA4A, TUBB4A, MYH11, 
TUBB, TUBB2B 
12 
TCA Cycle II 
(Eukaryotic) 
 
5.68 
 
CS, DLST, DLD, FH, IDH3B 
 
5 
mTOR Signal-
ing 
 
5.48 
 
PPP2CB,PPP2R1A,PRKAB2, 
PPP2CA, PPP2R2A, PRKAA2, 
RPS6KA3, EIF3J, EIF4G1, EIF3L 
11 
AMPK Signal-
ing 
 
5.09 
 
PPP2CB, PPP2R1A, PRKAB2, 
CKM, PPP2CA, PPP2R2A, 
PRKAA2, PRKAG1, PRKAR1A 
9 
Protein Ubiqui-
tination Path-
way 
 
4.3 
 
PSMB3+ND6:N6, PSMD11, 
PSMA6, USP14, HSP90AB1, 
CUL2, PSMA4, PSMC3, PSMB6, 
DNAJC7, PSMC5 
11 
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Regulation of 
eIF4 and 
p70S6K Signal-
ing 
 
3.93 
 
PPP2CB, PPP2R1A, PPP2CA, 
PPP2R2A, EIF2S3, EIF3J, 
EIF4G1, EIF3L 
8 
Protein Kinase 
A Signaling 
 
3.35 
 
FLNB, MYL10, CAMK2D, 
PPP3CB, MYL2, MYL6, PPP1R7, 
MYL6B, ACP1, PRKAG1, 
PRKAR1A, CAMK2G 
12 
PPARα/RXRα 
Activation 
 
2.07 
 
MAP2K6, PRKAB2, HSP90AB1, 
PRKAA2, PRKAG1, PRKAR1A 
6 
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Table 6. Interaction partners that showed significant difference (decreased) upon 
insulin stimulation 
 
  
Gene 
name 
Protein Function 
ARCN1 Archain1 (Coatomer Protein Complex, 
Subunit Delta) 
Vesicle traffic 
ARF4 Adp-ribosylation factor 4 Vesicular trafficking and activators of 
phospholipase D 
  
COPA Coatomer protein complex, subunit al-
pha 
Vesicle traffic 
GYG1 Glycogenin 2 Primer for glycogen synthesis 
PSMC3 Proteasome (prosome, macropain) 26S 
subunit, atpase, 3 
Degradation of proteins 
RPL11 Ribosomal protein L11 rRNA maturation and formation of 
the 60S ribosomal subunits 
SCFD1 Sec1 family domain containing 1 Vesicular transport between the endo-
plasmic reticulum and the Golgi 
STAT3 Signal transducer and activator of tran-
scription 3 (acute-phase response fac-
tor) 
Transcription factor  
TUBB6 Tubulin, beta 6 class V Microtubule protein 
VAT1 Vesicle amine transport 1 Vesicle transporter 
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Table 7. Interaction partners that showed significant difference (increased) upon 
insulin stimulation: 
Gene name Protein Function 
ADSL 
Adenylsuccinate lyase 
Catalyzes steps in denovo AMP 
synthesis 
ATP5B 
ATP synthase, H+ transporting, mito-
chondrial F1 complex, beta polypeptide 
Subunit of Mitochondrial pro-
tein ATP Synthase; production 
of ATP 
DLD Dihydrolipoamide dehydrogenase Mitochondrial enzyme 
NT5C3 5'-nucleotidase, cytosolic IIIA Breakdown of nucleotides 
PGM1 
Phosphoglucomutase 1 
Glucose-1-phosphate to glucose 
6 phosphate and Vice versa 
PPP1R7 
Protein phosphatase 1, regulatory subunit 
7 
Dephosphorylation of proteins 
PPP2R2A 
Protein phosphatase 2, regulatory subunit 
B, alpha 
Dephosphorylation of proteins 
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 Type 2 Diabetes is a metabolic disorder associated with insulin resistance and 
consequent high blood glucose levels. Maximum glucose disposal takes place in skel-
etal muscle and studying skeletal muscle insulin resistance is crucial. Protein Phospha-
tase 2A (PP2A) is one of the major serine/threonine phosphatases belonging to Phos-
phoProteinPhosphatase (PPP) family. It constitutes about 80% of all serine/threonine 
phosphatases. It is regulated by numerous regulatory subunits as well as other substrate 
molecules and post translational modifications. This alters their localization, activity 
and also its target molecules. Many evidences show the effect of insulin on PP2Ac and 
its abnormal regulation in conditions of glucolipotoxicity. Thus, studying PP2Ac inter-
action partners in respect to type 2 diabetes will give insight into its role in insulin 
resistance. 
           Here, we studied interaction partners of PP2Ac in obese insulin resistant human 
subjects. Two skeletal muscle biopsies, basal and insulin stimulated are obtained from 
each individual using hyperinsulenemic euglycemic clamp technique. Using ESI-
HPLC-MS/MS, we identified 186 interaction partners. Out of which 14 partners were 
previously identified by other groups which leaves 172 novel partners. This is the larg-
est PP2Ac interaction network found till date. We also identified 17 insulin responsive 
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PP2Ac partners. Several important PP2Ac interaction partners molecules were identi-
fied, for the 1st time, in skeletal muscle from humans. Among them,, some are known 
to affect PP2Ac activity and others are significantly associated with insulin signaling. 
Further validation of these partners will help with a better understanding of the role and 
regulation of PP2Ac in terms of insulin resistance in obese individuals.   
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